tiprankstipranks
Trending News
More News >
ProQR (PRQR)
NASDAQ:PRQR

ProQR (PRQR) AI Stock Analysis

Compare
1,034 Followers

Top Page

PR

ProQR

(NASDAQ:PRQR)

43Neutral
ProQR's overall stock score reflects a company facing significant financial challenges, including persistent losses and negative cash flows. While revenue growth and a stable balance sheet are positives, the bearish technical indicators and negative valuation metrics highlight ongoing concerns about profitability and market sentiment. The stock appears oversold, suggesting potential for recovery if financial conditions improve.
Positive Factors
Financial Position
PRQR ended with $156M in cash, which management estimates is sufficient runway into mid-2027.
Market Opportunity
PRQR's RNA editing therapy, targeting the bile acid transporter for cholestatic diseases, addresses a multi-billion-dollar market, presenting a substantial long-term opportunity.
Partnerships
ProQR continues to execute on its partnership with Lilly, which includes potential data updates and milestone income.
Negative Factors
Market Challenges
The continued stock decline following a mid-October spike suggests recent market challenges for PRQR.
Past Setbacks
Catalysts are expected to return after a multi-year pipeline reset following the LCA10 failure, with key developments anticipated in the coming years.

ProQR (PRQR) vs. S&P 500 (SPY)

ProQR Business Overview & Revenue Model

Company DescriptionProQR Therapeutics N.V. is a biotechnology company focused on the development of innovative RNA therapies for the treatment of genetic disorders. Headquartered in the Netherlands, ProQR primarily operates within the pharmaceutical and healthcare sectors. The company's core products are based on its proprietary RNA repair platform, which targets genetic mutations at the molecular level to treat rare diseases, with an emphasis on inherited retinal diseases and other genetic conditions.
How the Company Makes MoneyProQR Therapeutics generates revenue through a combination of strategic collaborations, partnerships, and licensing agreements with other pharmaceutical and biotechnology companies. These agreements often involve upfront payments, milestone payments based on the achievement of certain development or regulatory goals, and royalties on future sales of any successfully developed products. Additionally, ProQR may receive funding from government grants and research institutions to support its innovative RNA-based drug development programs. The company's focus on addressing unmet medical needs in rare genetic disorders positions it to potentially benefit from orphan drug designations, which can provide market exclusivity and other financial incentives.

ProQR Financial Statement Overview

Summary
ProQR is experiencing revenue growth, which is promising for future operations. Nevertheless, persistent losses and negative cash flows highlight financial challenges. The company's balance sheet remains relatively stable, supported by strong cash reserves, but profitability and cash flow improvements are needed for long-term sustainability.
Income Statement
40
Negative
ProQR's revenue has shown significant growth from 2023 to 2024, indicating positive development in sales. However, the company continues to face substantial net losses and negative EBIT and EBITDA margins, which suggests ongoing operational challenges and profitability issues.
Balance Sheet
55
Neutral
The company's balance sheet reflects a moderate debt-to-equity ratio, indicating manageable leverage levels. However, the equity ratio has decreased, implying a reduction in the company's financial stability. The consistent increase in cash and short-term investments is a positive sign, enhancing liquidity.
Cash Flow
45
Neutral
Free cash flow has deteriorated significantly in 2024 compared to 2023, raising concerns about cash generation. The operating cash flow to net income ratio is negative, indicating cash flow issues relative to net losses. The company benefits from strong financing activities, boosting cash reserves.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
18.91M6.51M4.04M1.35M0.00
Gross Profit
18.91M6.38M1.56M1.35M-2.19M
EBIT
-30.47M-31.86M-64.72M-57.19M-42.37M
EBITDA
-24.12M-24.10M-56.46M-54.95M-136.56M
Net Income Common Stockholders
-27.76M-28.12M-64.89M-61.68M-46.61M
Balance SheetCash, Cash Equivalents and Short-Term Investments
149.41M118.92M94.78M187.52M75.84M
Total Assets
167.96M137.88M171.32M209.58M98.73M
Total Debt
17.22M19.73M21.97M60.37M34.28M
Net Debt
-132.19M-99.19M-72.80M-127.15M-41.56M
Total Liabilities
79.40M96.49M106.21M96.35M42.18M
Stockholders Equity
88.56M41.39M65.50M113.83M57.09M
Cash FlowFree Cash Flow
-37.81M20.18M-69.22M-26.50M-47.98M
Operating Cash Flow
-36.39M21.55M-68.51M-26.01M-47.06M
Investing Cash Flow
-4.07M4.28M-702.00K-425.00K-924.00K
Financing Cash Flow
70.28M-2.27M-30.89M136.83M14.50M

ProQR Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.66
Price Trends
50DMA
1.68
Negative
100DMA
2.13
Negative
200DMA
2.32
Negative
Market Momentum
MACD
-0.03
Negative
RSI
60.42
Neutral
STOCH
84.68
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRQR, the sentiment is Negative. The current price of 1.66 is above the 20-day moving average (MA) of 1.29, below the 50-day MA of 1.68, and below the 200-day MA of 2.32, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 60.42 is Neutral, neither overbought nor oversold. The STOCH value of 84.68 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRQR.

ProQR Risk Analysis

ProQR disclosed 79 risk factors in its most recent earnings report. ProQR reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

ProQR Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
58
Neutral
$134.66M87.50-23.63%-16.72%26.35%
52
Neutral
$231.19M-95.00%44.85%
52
Neutral
$5.38B3.59-41.63%2.87%17.72%1.87%
50
Neutral
$117.13M-106.12%29.94%-241.81%
SLSLN
46
Neutral
$163.31M-99.23%-40.10%-16.60%
45
Neutral
$118.97M-23.91%-13.92%-2.86%
43
Neutral
$174.65M-43.72%190.40%7.54%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PRQR
ProQR
1.66
-0.33
-16.58%
CGEN
Compugen
1.60
-0.56
-25.93%
RGLS
Regulus
7.98
5.29
196.65%
TNXP
Tonix Pharma
18.01
-529.51
-96.71%
SLN
Silence Therapeutics
3.70
-17.60
-82.63%
SEER
Seer
1.99
-0.17
-7.87%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.